Drug Trial Radar · NCT03392116
Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Aug 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
Jan 29, 2018
Primary completion
Jan 14, 2019
Study completion Mar 11, 2019
Sponsor
- Lead sponsor
- NGM Biopharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects
Conditions
- Cachexia
Interventions
NGM120Biological
Subcutaneous Injection
PlaceboOther
Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A Arm-Single Dose: Treatment Emergent Adverse eventsTime frame: 28 days
- Part B Arm-Multiple Dose: Treatment Emergent Adverse eventsTime frame: 84 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Limited
Melbourne, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.